Evidence map›Paper›PMID 32148364›Full record

ArticleJournal of pharmacy & bioallied sciences2019

Optimization of Secreted Recombinant Human Epidermal Growth Factor Production Using Pectate Lyase B from

Sriwidodo Sriwidodo, Toto Subroto, Iman P Maksum, Nasrul Wathoni, Tina Rostinawati, Himmatul Ulya, Indah U Putri

Open access · goldAbstract read
In one paragraph

Article in Journal of pharmacy & bioallied sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Activity and Effectiveness of Recombinant hEGF Excreted byJournal of experimental pharmacology · 2020
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sriwidodo SriwidodoDepartment of Pharmaceutic and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Jawa Barat, Indonesia.
Toto SubrotoDepartment of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Padjadjaran, Sumedang, Jawa Barat, Indonesia.
Iman P MaksumDepartment of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Padjadjaran, Sumedang, Jawa Barat, Indonesia.
Nasrul WathoniDepartment of Pharmaceutic and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Jawa Barat, Indonesia.
Tina RostinawatiDepartment of Biology Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Jawa Barat, Indonesia.
Himmatul UlyaDepartment of Biology Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Jawa Barat, Indonesia.
Indah U PutriDepartment of Biology Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Jawa Barat, Indonesia.
Padjadjaran University · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextHuman Epidermal Growth Factor (hEGF) is a potential therapeutic protein that has been widely used as a healing agent for various chronic wounds. It induces the proliferation and metabolism of epithelial cells, regenerates skin cells, and validates skin elasticity. In the previous study, recombinant hEGF (rhEGF) had been successfully expressed extracellularly in Escherichia coli (E. coli) BL21 (DE3) using pectate lyase B (PelB) signal peptide. The previous study has shown that the medium concentration and the induction time influenced the production of rhEGF.

aimsTherefore, this study was conducted to optimize the induction time and medium concentration for rhEGF extracellular secretion then followed by scale-up production. SETTINGS AND

designThis experiment was carried out using E. coli BL21 (DE3) which contains pD881 plasmid that carries hEGF and PelB gene. Optimization design of induction time and medium concentration were obtained using Central Composite Design (CCD). METHODS AND MATERIAL: The method of study started by the rejuvenation of E. coli culture, extracellular secretion, and optimization in the flask scale then followed by scaled-up production with high-cell density culture in the fermenter. STATISTICAL ANALYSIS USED: The optimization was carried out using Response Surface Methodology (RSM) and multi regression analysis.

resultsThis work showed that the multiplication of 1.5-fold medium concentration with induction time 3h after the culture started gave the best result among another condition in this study. Additionally, the rhEGF production in the fermenter scale was identified by SDS-PAGE Tricine and quantified by ELISA, which showed 122.40 μg of the rhEGF per milliliter medium.

conclusionsIn respect of the result, we conclude that the optimized condition of extracellular secretion was successfully obtained, and gives higher result before the previous study.

Indexed as

Central composite designEscherichia coli BL21(DE3)high cell-density culturerecombinant human epidermal growth factor

Identifiers

PMID32148364
PMCPMC7020833
OpenAlexW2997033143

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.